Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
LYEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $3.26
Previous CloseN/A
Volume124.06K
Average Volume (3M)1.13M
Market Cap
$178.04M
Enterprise Value-$28.27M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Feb 26, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding292,161,650
10 Day Avg. Volume1,766,493
30 Day Avg. Volume1,134,791
Standard Deviation0.25
R-Squared0.00497
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2700.91
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-217.43
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$2.30Price Target Upside248.48% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
---
Lyell Immunopharma News
PremiumCompany Announcements
Lyell Immunopharma Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is LYEL a Buy, Before Earnings?
PremiumCompany Announcements
Lyell Immunopharma’s Strategic Moves and Leadership Expansion---
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of ImmPACT Biosciences focuses Lyell Immunopharma on a promising CAR-T cell therapy for B-cell lymphomas.
Financial PositionLyell ended 3Q24 with $461M in cash, which management expects to provide an operational runway into 2027.
Pipeline DevelopmentEncouraging efficacy signals were produced by solid-tumor CAR-Ts, despite the discontinuation of the TIL program.
Bears Say
Competitive LandscapeCompeting with established players like Gilead, Bristol, and Novartis is likely to be challenging, especially given their sizeable infrastructure investments.
Market OpportunityThe CD19-targeted CAR-T space is crowded, and the opportunity for another entrant like Lyell is limited.
Strategic UncertaintyThe decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.
---
Ownership Overview
17.47% Insiders
7.42% Mutual Funds
3.03% Other Institutional Investors
65.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $0.51 and its highest was $3.25 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $178.04M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Nov 07, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.025.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -0.17.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 292,161,650 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
---
Lyell Immunopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$2.30 (248.48% Upside)
$2.30 (248.48% Upside)
Blogger Sentiment
Neutral
LYEL Sentiment 50%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.77%
12-Months-Change
Fundamentals
Return on Equity
-33.22%
Trailing 12-Months
Asset Growth
-22.11%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
---
LYEL Stock 12 Month Forecast
Average Price Target
$2.30
▲(248.48% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering LYEL
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+4.80%
reiterated a sell rating last month
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +4.80% per trade.
---